JAK3 mutations and ectopic expression of HOXA9 are significantly associated in clinical T-ALL cases. JAK3 mutations and ectopic expression of HOXA9 are.

Slides:

Advertisements

Similar presentations

Homozygous deletions within chromosome 9q23.

Advertisements

SI-II A SI-II. Expression analysis of bladder cancer functionally active genes and significantly mutated genes. Comprehensive transcriptome profiling of.

T-ALL: Home Is where the CXCL12 Is

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

CD25 expression is associated with unfavorable clinical outcome.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Vegfa is overexpressed by E11

Somatic promoters correlate with immunoediting signatures.

Copy-number alterations in an archival breast cancer sample.

Potential clinical actionability.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

G34 induces a transcriptional program linked to forebrain development and self-renewal. G34 induces a transcriptional program linked to forebrain development.

Volume 23, Issue 1, Pages 9-22 (January 2013)

Pearson correlation of gene expression identifies distinct groups of male- and female-enriched genes. Pearson correlation of gene expression identifies.

Validation of RNA transcription profile differential expression using real-time quantitative PCR. Relative gene expression in cases compared with controls.

RNA-seq results at the SAM

AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)

Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.

Relative expression levels of known mRNA selected as points of reference. Relative expression levels of known mRNA selected as points of reference. mRNA.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

DNMT3A2 signatures are coherently modified in AML.

Dissection of oligoclonality.

Additional file 4: Comparison of RNA-Seq and RT-qPCR expression analyses of candidate genes between RIL165 and RIL387.

Schematic representation of a transcriptomic evaluation approach.

RT-PCR analysis of GFP splice variants in prp18a-1 mutants.

HoxA9 directly regulates cell cycle control genes.

Expression of cGMP signaling components in polyps.

CD25 expression identifies two transcriptionally distinct subsets of very early effector cells. CD25 expression identifies two transcriptionally distinct.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Fig. 2 HRI depletion elevates γ-globin in HUDEP2 cells.

NRG1 rearrangements are found in multiple solid tumors.

Expression analysis of IGFBP-3 using human whole-genome microarray.

EZH2 overexpression establishes a unique and conserved super-enhancer–associated transcriptional landscape. EZH2 overexpression establishes a unique and.

Fig. 1 A time-course RNA-seq analysis reveals prominent IRF8 expression in the spinal cord during the recovery phase after SCI. A time-course RNA-seq analysis.

Integrated mRNA and microRNA expression and DNA methylation clusters.

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

JAK2V617F leads to increased 5-hmC and genome-wide loss of cytosine methylation in primary patient samples. JAK2V617F leads to increased 5-hmC and genome-wide.

JAK2V617F leads to 5-hmC gain in vivo that correlates with gene expression. JAK2V617F leads to 5-hmC gain in vivo that correlates with gene expression.

A, scatterplots of qMSP analysis of candidate genes promoters in the prevalence screen cohort, which consisted of 55 HNSCC tumor tissue samples and 37.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

SAF-1 expression in clinical breast cancer tissues.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Discovered and replicated positive correlation between miR-193b

Location of common clinically relevant mutations in EGFR

Expression of S100A11 in bulk pancreatic tissues (pancreatic cancer, n = 22; IPMN, n = 18; nonneoplastic pancreas, n = 22). Expression of S100A11 in bulk.

CDK6 induces a transcriptional program to antagonize p53.

Gene expression profiles of T cells.

Distribution of FGFR aberrancies in urothelial cancers.

Reduced klotho expression in pancreatic cancer.

Location of the ER mutations and frequencies per cohort.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Antigen expression and Breslow thickness.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT signaling. HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT.

Host gene expression changes following exposure to the microbiota.

Defining the eTME genes.

IL-1β expression is increased in MM cell lines by the co-culture with platelets in vitro. IL-1β expression is increased in MM cell lines by the co-culture.

PIK3CA somatic mutation and amplification frequency in prostate cancer

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

EZH2-driven lung cancer as a molecularly distinct entity.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Mutational load and mutations in the interferon signaling pathway among patients with advanced melanoma with or without response to anti–PD-1 blockade.

Driver pathways and key genes in OSCC

Integrated analysis of gene expression and copy number alterations.

Mutant TERT promoter displays active histone marks and distinct long-range interactions: A, cell lines that were used in the study with their origin and.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. A, Treatment.

Cxxc1-deficient TH17 cells exhibit a Treg cell–like expression profile

Presentation transcript:

JAK3 mutations and ectopic expression of HOXA9 are significantly associated in clinical T-ALL cases. JAK3 mutations and ectopic expression of HOXA9 are significantly associated in clinical T-ALL cases. A, Frequency of IL7R/JAK/STAT mutations in 155 T-ALL cases (Vicente dataset) and 264 T-ALL cases (Liu dataset) within different defined transcription factor subgroups. Dotted line denotes average percentage of IL7R/JAK/STAT mutations across entire dataset. B, Association between JAK3 mutations only and defined transcription factor subgroups within the Vicente and Liu datasets. C, RNA-seq FPKM levels for JAK3 and HOXA9 in the Liu dataset. D, Real-time qPCR of primary T-ALL samples for HOXA9, HOXA10, and HOXA11. Charles E. de Bock et al. Cancer Discov 2018;8:616-631 ©2018 by American Association for Cancer Research